You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Genetically Engineered Autologous T Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Solid Tumors Trial in New York (procedure, drug, device, genetic)

Active, not recruiting
  • Solid Tumors
  • Production of Genetically-modified T cells
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Sep 1, 2022

Ovarian Cancer Trial in Tampa (Follicle Stimulating Hormone Receptor T Cells)

Recruiting
  • Ovarian Cancer
  • Follicle Stimulating Hormone Receptor T Cells
  • Tampa, Florida
    Moffitt Cancer Center
Mar 30, 2022

Malignant Pleural Disease, Mesothelioma, Metastases Trial in United States (iCasp9M28z T cell infusions, cyclophosphamide,

Active, not recruiting
  • Malignant Pleural Disease
  • +4 more
  • iCasp9M28z T cell infusions
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 14, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo

Active, not recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Aldesleukin
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 3, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Solid Tumor, Cancer, Recurrent Solid Tumors Trial in Germany, United States (IMA201 Product, IMADetect®)

Recruiting
  • Solid Tumor
  • +3 more
  • IMA201 Product
  • IMADetect®
  • Chicago, Illinois
  • +6 more
Dec 28, 2021

Metastatic HPV-16 Positive Squamous Cell Anal Cancer Trial run by the NCI (Cyclophosphamide, Fludarabine, Aldesleukin)

Withdrawn
  • Metastatic HPV-16 Positive Squamous Cell Anal Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 29, 2021

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 28, 2022

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 3, 2023

Trial (Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine)

No longer available
    • Individual Patient TCR Transduced PBL
    • +4 more
    • (no location specified)
    Sep 3, 2020

    Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

    Not yet recruiting
    • Myeloma
    • Fludarabine phosphate
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2023

    Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

    Completed
    • Sarcoma
    • +3 more
    • Anti-GD2-CAR engineered T cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 31, 2023

    Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

    Not yet recruiting
    • Prostate Carcinoma
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 17, 2023

    Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

    Not yet recruiting
    • Metastatic Colorectal Adenocarcinoma
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 12, 2023

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

    Recruiting
    • B Cell Malignancies
    • Universal CD19-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    Glioblastoma Trial in Birmingham (Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified

    Not yet recruiting
    • Glioblastoma
    • Autologous genetically modified gamma-delta T cells
    • Allogeneic genetically modified gamma-delta T cells
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Dec 16, 2022

    Metastatic Breast Cancer Trial in Duarte (huMNC2-CAR44 CAR T cells, huMNC2-CAR44 CAR T cells @ RP2D)

    Recruiting
    • Metastatic Breast Cancer
    • huMNC2-CAR44 CAR T cells
    • huMNC2-CAR44 CAR T cells @ RP2D
    • Duarte, California
      City of Hope Medical Center
    Dec 22, 2021